CLINICAL STAGE III ESOPHAGEAL ADENOCARCINOMA AJCC V8
Clinical trials for CLINICAL STAGE III ESOPHAGEAL ADENOCARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new CLINICAL STAGE III ESOPHAGEAL ADENOCARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for CLINICAL STAGE III ESOPHAGEAL ADENOCARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental combo targets incurable esophageal cancer
Disease control OngoingThis early-phase study tested a drug called adavosertib combined with radiation therapy for people with advanced esophageal or stomach cancer that cannot be surgically removed. The goal was to find the safest dose and see how well the combination works. Only 4 people took part, s…
Matched conditions: CLINICAL STAGE III ESOPHAGEAL ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 09:57 UTC
-
Immunotherapy combo shows promise in esophageal cancer fight
Disease control TerminatedThis study tests whether adding two immunotherapy drugs, nivolumab and ipilimumab, to standard chemotherapy and radiation helps people with esophageal or gastroesophageal junction cancer. About 278 adults with stage II to IVA cancer will receive the combination before and after s…
Matched conditions: CLINICAL STAGE III ESOPHAGEAL ADENOCARCINOMA AJCC V8
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
Virus-Enhanced treatment shows promise for Hard-to-Treat esophageal cancer
Disease control OngoingThis early-phase trial studies a new treatment for people with advanced esophageal or gastroesophageal cancer who cannot have surgery. It combines a cancer-killing virus (OBP-301) with standard chemotherapy and radiation. The main goal is to check safety and find the best dose, w…
Matched conditions: CLINICAL STAGE III ESOPHAGEAL ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: NRG Oncology • Aim: Disease control
Last updated May 20, 2026 11:54 UTC
-
New combo before surgery shows promise against esophageal cancer
Disease control OngoingThis study tests whether adding immunotherapy drugs (atezolizumab and tiragolumab) to standard chemotherapy before surgery can better control esophageal or gastroesophageal cancer. About 43 adults with stage II or III cancer will receive the drug combination, then undergo surgery…
Matched conditions: CLINICAL STAGE III ESOPHAGEAL ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 18, 2026 12:13 UTC